TELA - TELA Bio guides Q4 and FY20 revenue below consensus
TELA Bio (TELA) reports preliminary Q4 and FY 2020 results. Q4 rand FY20 revenue is expected to be $5.5M - $5.7M (consensus $6.03M) and $18.0M - 18.2M (est. $18.52M), respectively.Cash and equivalents at December 31, 2020 is expected to be $74.4M. "Our revenue in the fourth quarter continued to be impacted by the COVID-19 pandemic, as we experienced slowdowns in procedural volumes in many geographies," said Antony Koblish, President and CEO.The company will report actual Q4 and FY20 financial results in March 2021.
For further details see:
TELA Bio guides Q4 and FY20 revenue below consensus